LV12768B - Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām - Google Patents

Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām Download PDF

Info

Publication number
LV12768B
LV12768B LVP-01-62A LV010062A LV12768B LV 12768 B LV12768 B LV 12768B LV 010062 A LV010062 A LV 010062A LV 12768 B LV12768 B LV 12768B
Authority
LV
Latvia
Prior art keywords
agent
composition
soluble form
antibody
hemostatic
Prior art date
Application number
LVP-01-62A
Other languages
English (en)
Latvian (lv)
Other versions
LV12768A (en
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute, Inc.
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc., American Red Cross filed Critical Genetics Institute, Inc.
Publication of LV12768A publication Critical patent/LV12768A/en
Publication of LV12768B publication Critical patent/LV12768B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LVP-01-62A 1998-09-21 2001-04-20 Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām LV12768B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques

Publications (2)

Publication Number Publication Date
LV12768A LV12768A (en) 2001-12-20
LV12768B true LV12768B (lv) 2002-06-20

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-62A LV12768B (lv) 1998-09-21 2001-04-20 Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām

Country Status (21)

Country Link
EP (1) EP1115423A1 (fr)
JP (1) JP2002526455A (fr)
KR (1) KR20010085830A (fr)
CN (1) CN1331602A (fr)
AU (1) AU761206B2 (fr)
BR (1) BR9913991A (fr)
CA (1) CA2343916A1 (fr)
CZ (1) CZ20011021A3 (fr)
EA (1) EA005236B1 (fr)
HK (1) HK1039059A1 (fr)
HU (1) HUP0103960A3 (fr)
IL (1) IL142069A0 (fr)
LT (1) LT4920B (fr)
LV (1) LV12768B (fr)
MX (1) MXPA01002898A (fr)
NO (1) NO20011412L (fr)
NZ (1) NZ511034A (fr)
PL (1) PL346796A1 (fr)
SI (1) SI20626A (fr)
WO (1) WO2000016801A1 (fr)
ZA (1) ZA200103156B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP1289552B1 (fr) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Procedes pour des troubles hemostatiques par de la p-selectine soluble
EP1636579A4 (fr) * 2003-06-10 2011-10-05 Smiths Detection Inc Ensemble detecteur
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
CA1341174C (fr) 1985-04-12 2001-01-30 John J. Toole Jr. Proteines procoagulantes derivees du facteur viii: c
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
WO1993009804A1 (fr) 1991-11-18 1993-05-27 The Scripps Research Institute Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (fr) * 1994-08-19 1996-02-29 Novo Nordisk A/S Methode de traitement d'un patient a l'aide d'un compose biologiquement actif
JPH10507758A (ja) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
EP1034001B1 (fr) * 1997-06-20 2004-08-04 Biogen Idec MA Inc. Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
LT4920B (lt) 2002-06-25
BR9913991A (pt) 2001-07-03
IL142069A0 (en) 2002-03-10
NZ511034A (en) 2004-03-26
HUP0103960A2 (hu) 2002-02-28
WO2000016801A9 (fr) 2000-10-26
AU6057899A (en) 2000-04-10
WO2000016801A1 (fr) 2000-03-30
LT2001045A (en) 2002-01-25
MXPA01002898A (es) 2002-06-04
CA2343916A1 (fr) 2000-03-30
HUP0103960A3 (en) 2003-09-29
EA200100385A1 (ru) 2001-10-22
HK1039059A1 (zh) 2002-04-12
LV12768A (en) 2001-12-20
KR20010085830A (ko) 2001-09-07
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
SI20626A (sl) 2002-02-28
PL346796A1 (en) 2002-02-25
EA005236B1 (ru) 2004-12-30
NO20011412D0 (no) 2001-03-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18
AU761206B2 (en) 2003-05-29
EP1115423A1 (fr) 2001-07-18
NO20011412L (no) 2001-05-16

Similar Documents

Publication Publication Date Title
Alon et al. TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein.
White II et al. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A
CA2246352A1 (fr) Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
ES2210225T5 (es) Inhibición de la adherencia de los linfocitos al endotelio vascular mediante una nueva interacción receptor de matriz extracelular-ligando
CA2338005A1 (fr) Antagonistes peptidiques de la zonuline et techniques d'utilisation
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
CA2221730A1 (fr) Utilisation d'agonistes du recepteur type 2 de l'angiotensine ii dans la reparation des tissus
DK0735893T3 (da) PAN DR-bindende peptider til styrkelse af immunsvaret
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
EP1806364A3 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
NZ332995A (en) A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
WO1997030085B1 (fr) Sous-unites et fragments de troponine utiles comme inhibiteurs de l'angiogenese
PT902789E (pt) Derivados de androsteno
FI972703A (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
JPH0692318B2 (ja) 不要細胞の分解あるいは阻止物質からなる治療剤
CA2378613A1 (fr) Antagonistes selectifs du recepteur iglur5 utilises dans le traitement de la migraine
CA2233138A1 (fr) Inhibiteurs de recepteurs a l'integrine et leurs emplois therapeutiques
LV12768B (lv) Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām
CA2449488A1 (fr) Compositions et procedes pour traiter une reponse hyperimmune de l'oeil